Chloroquine
- Generic Name
- Chloroquine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
- Conditions
- Brain Metastasis
- Interventions
- Radiation: Total brain radiotherapy
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 73
- Registration Number
- NCT01894633
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico DF, DF, Mexico
Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
- Conditions
- Plasmodium Vivax Malaria
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-09-30
- Target Recruit Count
- 330
- Registration Number
- NCT01887821
- Locations
- 🇻🇳
Bu Gia Map Health Station, Bu Gia Map, Binh Phuoc, Vietnam
Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
- Conditions
- AnaemiaHyper-reactive Malarial SplenomegalyMalaria
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Lihir Medical Centre
- Registration Number
- NCT01785979
- Locations
- 🇵🇬
Lihir medical Centre, Londolovit, New ireland province, Papua New Guinea
Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria
- Conditions
- Parasitemia
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Ministry of Health, Bhutan
- Target Recruit Count
- 50
- Registration Number
- NCT01784315
- Locations
- 🇧🇹
Vector Diseases Control Program, Gelephu, Gelephu, Bhutan
🇧🇹Mr. Thinly, Sarpang, Bhutan
Adjuvant Effect of Chloroquine on Gemcitabine
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 9
- Registration Number
- NCT01777477
- Locations
- 🇨🇭
University Hospital Zurich, Department of Oncology, Zurich, ZH, Switzerland
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Main Line Health
- Target Recruit Count
- 20
- Registration Number
- NCT01727531
- Locations
- 🇺🇸
Lankenau Medical Center, Wynnewood, Pennsylvania, United States
Vascular Function Intervention Trial in Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Dietary Supplement: Regular Ready-to-use supplementary foodDietary Supplement: Vascular ready-to-use supplementary food
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT01718054
- Locations
- 🇹🇿
Muhimbili University of Heath and Allied Sciences (MUHAS), Dar es Salaam, Tanzania
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Menzies School of Health Research
- Target Recruit Count
- 24
- Registration Number
- NCT01716260
- Locations
- 🇧🇹
Vector Diseases Control Program, Gelephu, Bhutan
P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine
- Conditions
- Uncomplicated Plasmodium Knowlesi Malaria
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Menzies School of Health Research
- Target Recruit Count
- 250
- Registration Number
- NCT01708876
- Locations
- 🇲🇾
Kudat District Hospital, Kudat, Sabah, Malaysia
🇲🇾Kota Marudu District Hospital, Kota Marudu, Sabah, Malaysia
🇲🇾Pitas District Hospital, Pitas, Sabah, Malaysia
Ethiopia Antimalarial in Vivo Efficacy Study 2012
- Conditions
- Plasmodium Vivax Infection
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 398
- Registration Number
- NCT01680406
- Locations
- 🇪🇹
Bishoftu Malaria Center, Debre Zeit, Ethiopia
🇪🇹Batu Health Center, Zeway, Ethiopia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.